Enzyme within cancer cells prevents immune system from fighting disease
An enzyme in cancer cells called aconitate decarboxylase (Acod1) appears to cause the release of short chains of amino acids, called peptides, that interfere with the way our bodies’ immune cells fight the disease, a new study by University of Notre Dame cancer biologist Zachary Schafer shows.
According to a research article in Cell Reports, cancer cells with high levels of Acod1, located in the mitochondria — the “powerhouses” of cells — were discovered to decrease the effectiveness of a certain type of cancer therapy called immune checkpoint inhibitor therapy. These drugs block protein “checkpoints” made by our immune system’s T cells and some cancer cells, preventing the T cells from killing the cancer. This type of cancer immunotherapy has proven to be effective in some cancers like melanomas, but not for cancers including prostate cancer, according to Schafer, the Coleman Foundation Associate Professor of Cancer Biology in the Department of Biological Sciences.
Previous research on Acod1, including another recent study in the lab of Xin Lu, the John M. and Mary Jo Boler Collegiate Associate Professor in the Department of Biological Sciences, has been focused on how Acod1 impacts the behavior and function of immune cells themselves.
“Our research shows that the cancer cells can use this enzyme as well. Surprisingly, Acod1 activity in cancer cells dampens the immune response, which is a really novel and exciting discovery,” said Schafer, who is affiliated with the Harper Cancer Research Institute.

As part of the experiments described in Schafer’s paper, researchers reduced the levels of Acod1 inside of prostate cancer cells. Next, the researchers introduced those altered cells into mouse models. Once the levels of Acod1 in the cancer cells were reduced, the immune checkpoint inhibitor therapy worked: The T cells rushed in to do their job, diminishing the cancer.
This project grew out of research in Schafer’s lab from 2018, when his group discovered a novel cancer cell death pathway involving changes in the mitochondria. Following that paper, his lab discovered that the cancer cells that were defective in this cell death pathway were also resistant to immune checkpoint inhibitors. He and collaborators then determined that, as a result of the significant changes in the mitochondria, Acod1 was responsible for the resistance to immune checkpoint inhibitors.
“That the cancer cells are better able to evade the immune response is totally dependent on this Acod1 enzyme,” Schafer said. “It’s definitely antagonizing the effect of the T-cells.”
Schafer and members of his lab are continuing to explore the effects of Acod1 for future studies. For instance, Schafer is interested in how Acod1 causes the production of the peptides, and he does not yet know the precise configuration of the amino acids in the peptides released by cancer cells with Acod1.
“We do not yet know how the T cells interact with these peptides, which is the other thing is that we are trying to figure out,” Schafer said.
This study was led by recent Notre Dame Ph.D. graduate James H. Schofield. In addition to Schafer and Schofield, other authors on the study are Emma Albano, Mark A. Hawk, Sean Murphy, Loan Duong, Sharif Rahmy,and Xin Lu, all from the University of Notre Dame, as well as Abigail E. Ellis, Joseph Longo, Russell G. Jones and Ryan D. Shelton of the Van Andel Institute, Grand Rapids, Michigan.
The paper was funded by the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, the Coleman Foundation, and the Malanga Family Excellence Fund for Cancer Research, and the College of Science and Department of Biological Sciences at Notre Dame.
Originally published by science.nd.edu on May 16, 2024.
atLatest Research
- Lieberman wins public interest award from the American Chemical SocietyMarya Lieberman, professor in the Department of Chemistry and Biochemistry, has been selected to receive the Gustavus John Esselen Award for Chemistry in the Public Interest for developing low-cost Paper Analytical Devices (PADs) used to identify substandard medicines.
- Sara Berger named as new IBM director of the Notre Dame–IBM Technology Ethics LabSara Berger, IBM director of the Notre Dame–IBM Technology Ethics Lab…
- University of Notre Dame wins award for excellence in campus internationalizationIn recognition of its outstanding commitment to internationalization both on campus and across the globe, the University of Notre Dame has been selected to receive the 2025 Senator Paul Simon Award for Comprehensive Internationalization. Named for the late Sen. Paul Simon, a longtime proponent of international education, the award is given by NAFSA: Association of International Educators to honor excellence in integrating international education throughout all facets of university and college campuses.
- Notre Dame Law School’s Religious Liberty Clinic Secures Asylum for Iranian Christian Convert Facing PersecutionStudents from Notre Dame Law School’s Lindsay and Matt Moroun Religious Liberty Clinic recently helped secure asylum for an Iranian Christian convert who fled Iran after facing severe religious persecution. The case highlights the critical role of legal…
- Notre Dame Rome signs agreement with Rome’s Sovrintendenza Capitolina ai Beni CulturaliThis September Notre Dame Rome signed a three-year agreement with Sovrintendenza Capitolina…
- Notre Dame J.S.D. Candidate Khawla Wakkaf Receives Prestigious ITLOS-Nippon FellowshipJ.S.D. candidate Khawla Wakkaf has achieved a remarkable milestone as the first Syrian national and Notre Dame Law School student to receive the prestigious ITLOS-Nippon Fellowship. Awarded by the International Tribunal for the Law of the Sea in collaboration with the Nippon Foundation, the ITLOS-Nippon Fellowship provides advanced training to a select group of up to seven junior to mid-level governmental officials and researchers. Participants engage with pressing issues related to the law of the sea, maritime law, and dispute settlement mechanisms. Wakkaf earned this distinguished opportunity following nominations from Notre Dame Law School, namely Professor Paolo Carozza and Professor Paul Miller, and the Law School's International and Graduate Programs.